Acro Biomedical Co., Ltd.
ACBMOTCHealthcare● Active
$0.03
+$0.00(+0.00%)
Market Cap$1561092
P/E Ratio—
52W High$0.1
52W Low$0.0007
Acro Biomedical Co., Ltd. (ACBM) · Income Statement
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · ACBM · as of 2026-06-09
Financial statements
Revenue · Gross Profit · Net Income
| Breakdown | 2025-12 | 2024-12 | 2023-12 | 2022-12 | 2021-12 |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Cost of Revenue | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Gross Profit | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Gross Margin %(computed) | — | — | — | 21.34% | 21.67% |
| Operating Expenses | |||||
| R&D Expenses | $0.00B | $0.00B | $0.00B | $0.01B | $0.01B |
| G&A Expenses | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Total Operating Expenses | $0.00B | $0.00B | $0.01B | $0.02B | $0.01B |
| Operating Income | ($0.00B) | ($0.00B) | ($0.01B) | ($0.02B) | ($0.01B) |
| Operating Margin %(computed) | — | — | — | — | -642.47% |
| Interest Income | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Interest Expense | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Income Before Tax | ($0.00B) | ($0.00B) | ($0.01B) | ($0.02B) | ($0.01B) |
| Income Tax Expense | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Net Income | ($0.00B) | ($0.00B) | ($0.01B) | ($0.02B) | ($0.01B) |
| Net Margin %(computed) | — | — | — | — | -643.18% |
| Per Share & EBITDA | |||||
| EPS (Basic) | $-0.00 | $-0.00 | $-0.15 | $-0.26 | $-0.14 |
| Wtd Avg Shares | 0.06B | 0.06B | 0.06B | 0.06B | 0.05B |
| EBITDA | ($0.00B) | ($0.00B) | $0.00B | ($0.02B) | $0.00B |
| EBITDA Margin %(computed) | — | — | — | — | 0.00% |
Data source: Financial Modeling Prep · Last updated: 2026-06-09 · USD · B
Explore more Acro Biomedical Co., Ltd. data
About Acro Biomedical Co., Ltd. (ACBM) Income Statement
Acro Biomedical Co., Ltd. (ACBM) income statement data is sourced from SEC Form 10-K and 10-Q filings. For fiscal year 2025, ACBM reported revenue of $0.00B, gross profit of $0.00B (gross margin —), and net income of ($0.00B) — a net profit margin of —.
Frequently asked questions
ACBM · 4 questionsAcro Biomedical Co., Ltd. (ACBM) reported revenue of $0.00B for 2025, down —% year-over-year.
ACBM revenueACBM salesannual revenue YoYincome statement
· Source: FMP /stable/income-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-09